
HOOKIPA Pharma Inc. Reports Q1 Net Loss of $18M
HOOKIPA Pharma Inc. (HOOK) today reported financial results and business highlights for the first quarter of 2022.“We observed strong external validation of our novel arenaviral platform in...
HOOKIPA Pharma Inc. (HOOK) today reported financial results and business highlights for the first quarter of 2022.“We observed strong external validation of our novel arenaviral platform in...
Friday's top analyst upgrades and downgrades included AppLovin, BioCryst Pharmaceuticals, Boeing, CF Industries, Coupa Software, Crocs, Dutch Bros, DigitalOcean, Gilead Sciences, IBM,...
Monday's top analyst upgrades and downgrades included Amazon.com, Apple, Caterpillar, Comcast, Comerica, Gilead Sciences, Intel, Lululemon Athletica and McDonald's.
RBC Capital Market views Gilead Sciences Inc's (NASDAQ: GILD) Q1 as a solid quarter, with a bottom-line beat reflecting Veklury cash flow boost, solid core business performance despite...
Gilead Sciences (NASDAQ:GILD) reported its Q1 results, with EPS of $2.12 coming in better than the consensus estimate of $1.81. Revenue grew 3% year-over-year to $6.6 billion, compared to...
Gilead Sciences (NASDAQ:GILD) reported Q1 EPS of $2.12, $0.31 better than the analyst estimate of $1.81. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of...
Investing.com - Gilead (NASDAQ:GILD) reported on Thursday first quarter {{erl-6365||earnings that beat analysts' forecasts and revenue that topped expectations. Gilead announced earnings...
How Gilead is positioning Veklury vs. such COVID antivirals as Paxlovid
The company has an oral version of its COVID-19 drug Veklury in a clinical trial.
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Protagonist's Ulcerative Colitis Study Disappoints With Higher Dose Of PN-943 Protagonist...
The FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental marketing application for Veklury (remdesivir) for pediatric COVID-19 patients older than 28 days. The approval covers...
The Food and Drug Administration said Monday it expanded the approval of Gilead Sciences Inc.'s Veklury to include pediatric patients between the ages of four weeks and 12 years old....
Monay's top analyst upgrades and downgrades included Advanced Micro Devices, Danaher, DoorDash, Freeport-McMoRan, Gap, Gilead Sciences, Huntington Bancshares, Independence Realty Trust,...
The U.S. Food and Drug Administration has lifted the partial clinical hold order on Gilead Sciences, Inc.'s (GILD) blood cancer drug combination trials. The hold was initially placed on five...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Aeglea Shares Additional Phase 3 Data In Inherited Metabolic Disease Aeglea BioTherapeutics...
The Food and Drug Administration's decision on Monday to lift the partial hold on Gilead Sciences Inc.'s magrolimab for two indications is "good news" for the company, according to RBC...
The FDA has lifted the partial clinical hold on Gilead Sciences Inc's (NASDAQ: GILD) studies evaluating magrolimab combined with azacitidine. The FDA removed the partial clinical hold...
Gilead Sciences, Inc. (Nasdaq: NASDAQ:GILD) announced that the U.S. Food and Drug Administration (FDA) decided to remove its partial clinical hold on the company's studies investigating...
The U.S. Food and Drug Administration has lifted a partial clinical hold on studies evaluating magrolimab in combination with azacitidine, Gilead Sciences Inc. said Monday.
LEXINGTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response...
The FDA approved the expanded use of Gilead Sciences Inc's (NASDAQ: GILD) Yescarta, a cell therapy made by the Kite Pharma unit. The approval covers Yescarta (axicabtagene ciloleucel) for...
Kite, a unit of biopharmaceutical company Gilead Sciences (NASDAQ: GILD), announced that the U.S. Food and Drug Administration (FDA) has approved its Yescarta CAR T-cell immunotherapy. The...
Investing.com - Gilead (NASDAQ:GILD) reported on Tuesday fourth quarter {{erl-6365||earnings that missed analysts' forecasts and revenue that topped expectations. Gilead announced earnings...
By Sam Boughedda Investing.com — Shares of Belgian pharmaceutical research company Galapagos NV ADR (NASDAQ:GLPG) are up more than 21% a day after the company appointed its new CEO. Citi...
By Dhirendra Tripathi Investing.com – Gilead Sciences stock (NASDAQ:GILD) fell more than 4% Friday as the maker of remdesivir said sales of non-Covid drugs would be lower in 2021 than...
Investing.com - Gilead (NASDAQ:GILD) reported on Thursday third quarter {{erl-6365||earnings that beat analysts' forecasts and revenue that topped expectations. Gilead announced earnings...
Investing.com - Gilead (NASDAQ:GILD) reported on Thursday second quarter {{erl-6365||earnings that beat analysts' forecasts and revenue that topped expectations. Gilead announced earnings...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, July 19th. Please refresh for updates. Zoom Video Communications (NASDAQ:ZM) stock fell 2.2% after the...
Photo by Sharon Seretlo/Gallo Images via Getty ImagesSouth Africa’s approach to its COVID-19 vaccine programme has been characterised by a large number of...
* Twitter (NYSE:TWTR) plunges on grim outlook* Chevron down as profit drops on weaker refining margins* U.S. consumer spending rebounds in March* Futures down: Dow 0.49%, S&P 0.62%, Nasdaq...
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)* Futures down: Dow 0.53%, S&P 0.65%, Nasdaq 0.83%By Shivani KumaresanApril 30...
Investing.com - Gilead (NASDAQ:GILD) reported on Thursday first quarter {{erl-6365||earnings that beat analysts' forecasts and revenue that fell short of expectations. Gilead announced...
* Apple nearly unchanged after strong quarterly results* Communication services leads gains among S&P 500 sectors* U.S. economy accelerates in Q1; jobless claims edge lower (Updates with...
* Apple higher after strong quarterly results* Communication services leads gains among S&P 500 sectors* U.S. economy accelerates in Q1; jobless claims edge lower* Indexes: Dow +0.53%, S&P...
* Apple slips despite strong quarterly results* Communication services leads gains among S&P 500 sectors* U.S. economy accelerates in Q1; jobless claims edge lower* Indexes: Dow up 0.12%,...
* Apple, Facebook jump on strong earnings* Communication services leads gains among S&P 500 sectors* U.S. economy accelerates in Q1; jobless claims edge lower* Indexes up: Dow 0.39%, S&P...
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)* Apple, Facebook jump on strong earnings* U.S. economy accelerates in Q1;...
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)* Futures up: Dow 0.52%, S&P 0.72%, Nasdaq 1.00%By Shivani KumaresanApril 29...
By Jesse Cohen Investing.com - Market participants are bracing for heightened volatility as the coming week will be dominated by several market-moving events, including a deluge of...
Investing.com - Gilead (NASDAQ:GILD) reported on Thursday fourth quarter {{erl-6365||earnings that beat analysts' forecasts and revenue that topped expectations. Gilead announced earnings...
By Noreen Burke Investing.com -- A big week for earnings, including reports from Amazon and Alphabet, stimulus negotiations in Washington and the first jobs report of 2021 will all be major...
(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Euro zone PMIs top estimates* Continental jumps, sharply hikes EBIT forecast* EU...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.